NASDAQ:CKPT Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CKPT Stock Alerts $2.05 +0.01 (+0.49%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.02▼$2.1050-Day Range$1.68▼$2.3252-Week Range$1.30▼$3.91Volume345,753 shsAverage Volume588,945 shsMarket Capitalization$48.24 millionP/E RatioN/ADividend YieldN/APrice Target$22.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Checkpoint Therapeutics alerts: Email Address Checkpoint Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,002.4% Upside$22.60 Price TargetShort InterestBearish18.20% of Float Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews Sentiment-0.23Based on 10 Articles This WeekInsider TradingSelling Shares$48,297 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.26 out of 5 starsMedical Sector306th out of 938 stocksPharmaceutical Preparations Industry134th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.60, Checkpoint Therapeutics has a forecasted upside of 1,002.4% from its current price of $2.05.Amount of Analyst CoverageCheckpoint Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.20% of the float of Checkpoint Therapeutics has been sold short.Short Interest Ratio / Days to CoverCheckpoint Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Checkpoint Therapeutics has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCheckpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Checkpoint Therapeutics is -0.63. Previous Next 2.1 News and Social Media Coverage News SentimentCheckpoint Therapeutics has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Checkpoint Therapeutics this week, compared to 1 article on an average week.Search Interest13 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.MarketBeat Follows8 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,297.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of Checkpoint Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Checkpoint Therapeutics Stock (NASDAQ:CKPT)Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Read More CKPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CKPT Stock News HeadlinesMarch 24, 2024 | finance.yahoo.comCheckpoint Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 23, 2024 | americanbankingnews.comCheckpoint Therapeutics (NASDAQ:CKPT) Stock Rating Reaffirmed by HC WainwrightMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 22, 2024 | finanznachrichten.deCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 22, 2024 | investorplace.comCKPT Stock Earnings: Checkpoint Therapeutics Misses EPS, Misses Revenue for Q4 2023March 22, 2024 | globenewswire.comCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | msn.comDUI Checkpoint Planned For Canyon Lake FridayMarch 18, 2024 | globenewswire.comCheckpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of DirectorsMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 11, 2024 | msn.comWest Virginia State Police will be conducting a Sobriety CheckpointMarch 9, 2024 | seekingalpha.comCKPT Checkpoint Therapeutics, Inc.March 4, 2024 | finance.yahoo.comCheckpoint Therapeutics, Inc. (CKPT)February 25, 2024 | msn.comLAPD DUI Checkpoint, Saturation Patrols Planned Through MondayFebruary 11, 2024 | msn.comThe Economy of This Palestinian Village Depended on Israel. Then the Checkpoint ClosedFebruary 6, 2024 | msn.comFinally: New Denver International Airport Security Checkpoint CompleteFebruary 5, 2024 | msn.comPinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are SellingFebruary 4, 2024 | msn.comCheckpoint Therapeutics Faces Nasdaq Compliance ChallengeFebruary 1, 2024 | msn.comCheckpoint Therapeutics Issues Unregistered Equity WarrantsJanuary 31, 2024 | msn.comCheckpoint Therapeutics Signs Major Securities AgreementJanuary 29, 2024 | marketwatch.comCheckpoint Therapeutics Shares Rise 17% After Direct Offering PricesJanuary 29, 2024 | msn.comCheckpoint Therapeutics to raise ~$14MJanuary 23, 2024 | news.yahoo.comWest Salem's Checkpoint 221 food cart pod opens pavilion with heated seating, indoor barJanuary 11, 2024 | finance.yahoo.comCheckpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology ConferenceDecember 20, 2023 | markets.businessinsider.comAnalyst Maintains Buy Rating for Checkpoint Therapeutics Amid FDA Setback, Citing Strong Approval Prospects and Market PotentialDecember 19, 2023 | finance.yahoo.comCheckpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit OutlookDecember 18, 2023 | bizjournals.comCancer drug maker blames manufacturer for FDA rejection as stock spiralsDecember 18, 2023 | marketwatch.comCheckpoint Therapeutics Gets FDA Response Letter on Cosibelimab ApplicationSee More Headlines Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CKPT CUSIPN/A CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$22.60 High Stock Price Target$47.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,002.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,850,000.00 Net Margins-50,336.89% Pretax Margin-50,336.89% Return on EquityN/A Return on Assets-950.01% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.10 Sales & Book Value Annual Sales$100,000.00 Price / Sales482.37 Cash FlowN/A Price / Cash FlowN/A Book Value($1.89) per share Price / Book-1.08Miscellaneous Outstanding Shares23,530,000Free Float22,491,000Market Cap$48.24 million OptionableOptionable Beta1.00 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. James F. Oliviero III (Age 48)C.F.A., President, CEO & Director Comp: $891kMr. William Garrett Gray (Age 37)CFO, Corporate Secretary & Treasurer Comp: $365.75kKey CompetitorsOcuphire PharmaNASDAQ:OCUPRockwell MedicalNASDAQ:RMTIGain TherapeuticsNASDAQ:GANXDaré BioscienceNASDAQ:DAREEyenoviaNASDAQ:EYENView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 114,200 shares on 3/15/2024Ownership: 0.694%Vanguard Group Inc.Bought 65,671 shares on 3/11/2024Ownership: 2.330%James F Oliviero IIISold 5,894 sharesTotal: $12,141.64 ($2.06/share)William Garrett GraySold 2,035 sharesTotal: $4,212.45 ($2.07/share)Vanguard Group Inc.Bought 65,671 shares on 2/15/2024Ownership: 2.330%View All Insider TransactionsView All Institutional Transactions CKPT Stock Analysis - Frequently Asked Questions Should I buy or sell Checkpoint Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares. View CKPT analyst ratings or view top-rated stocks. What is Checkpoint Therapeutics' stock price target for 2024? 5 brokers have issued 12-month price objectives for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they predict the company's stock price to reach $22.60 in the next twelve months. This suggests a possible upside of 1,002.4% from the stock's current price. View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts. How have CKPT shares performed in 2024? Checkpoint Therapeutics' stock was trading at $2.29 on January 1st, 2024. Since then, CKPT shares have decreased by 10.5% and is now trading at $2.05. View the best growth stocks for 2024 here. Are investors shorting Checkpoint Therapeutics? Checkpoint Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,670,000 shares, an increase of 9.6% from the February 29th total of 3,350,000 shares. Based on an average trading volume of 654,100 shares, the short-interest ratio is currently 5.6 days. Approximately 18.2% of the company's stock are sold short. View Checkpoint Therapeutics' Short Interest. When is Checkpoint Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CKPT earnings forecast. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) issued its quarterly earnings data on Friday, March, 22nd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.36. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.09 million. When did Checkpoint Therapeutics' stock split? Shares of Checkpoint Therapeutics reverse split on Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL). Who are Checkpoint Therapeutics' major shareholders? Checkpoint Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (10.31%), Vanguard Group Inc. (2.33%), Vanguard Group Inc. (2.33%), B. Riley Wealth Advisors Inc. (0.69%), Northern Trust Corp (0.17%) and Simplex Trading LLC (0.00%). Insiders that own company stock include James F Oliviero III and William Garrett Gray. View institutional ownership trends. How do I buy shares of Checkpoint Therapeutics? Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CKPT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.